502 related articles for article (PubMed ID: 25891153)
41. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
[TBL] [Abstract][Full Text] [Related]
42. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
43. Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice.
McKay C; Burke T; Cao X; Abernethy AP; Carbone DP
Clin Lung Cancer; 2016 Sep; 17(5):449-460.e7. PubMed ID: 27157534
[TBL] [Abstract][Full Text] [Related]
44. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma.
Liao BC; Shao YY; Chen HM; Shau WY; Lin ZZ; Kuo RN; Lai CL; Chen KH; Cheng AL; Yang JC; Lai MS
Clin Lung Cancer; 2015 Mar; 16(2):137-43. PubMed ID: 25450871
[TBL] [Abstract][Full Text] [Related]
45. Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.
Roth JA; Goulart BH; Ravelo A; Kolkey H; Ramsey SD
Oncologist; 2017 Mar; 22(3):304-310. PubMed ID: 28242792
[TBL] [Abstract][Full Text] [Related]
46. Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system.
Pérez-Moreno MA; Cotrina-Luque J; Galván-Banqueri M; Flores-Moreno S; Bautista-Paloma FJ; Calleja-Hernández MÁ
J Chemother; 2015; 27(6):371-7. PubMed ID: 25971603
[TBL] [Abstract][Full Text] [Related]
47. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
Wu XY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.
Noonan K; Tong KM; Laskin J; Zheng YY; Melosky B; Sun S; Murray N; Ho C
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):505-13. PubMed ID: 26095646
[TBL] [Abstract][Full Text] [Related]
49. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts JG; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
Lung Cancer; 2015 Dec; 90(3):427-32. PubMed ID: 26791802
[TBL] [Abstract][Full Text] [Related]
50. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
51. Real-world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: Results from a retrospective chart review of patients with advanced/metastatic non-small cell lung cancer in the EU5.
Slowley A; Phiri K; Multani JK; Casey V; Mpima S; Yasuda M; Chen CC; Manuguid F; Chao J; Aziez A; Bell KF; Stojadinovic A
Thorac Cancer; 2023 Oct; 14(28):2846-2858. PubMed ID: 37592826
[TBL] [Abstract][Full Text] [Related]
52. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer.
Younes RN; Pereira JR; Fares AL; Gross JL
Rev Assoc Med Bras (1992); 2011; 57(6):686-91. PubMed ID: 22249550
[TBL] [Abstract][Full Text] [Related]
53. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Campbell D; O'Day K; Hertel N; Penrod JR; Manley Daumont M; Lees M
Popul Health Metr; 2018 Nov; 16(1):17. PubMed ID: 30477516
[TBL] [Abstract][Full Text] [Related]
54. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
Lee DH; Tsao MS; Kambartel KO; Isobe H; Huang MS; Barrios CH; Khattak A; de Marinis F; Kothari S; Arunachalam A; Cao X; Burke T; Valladares A; de Castro J
PLoS One; 2018; 13(8):e0202865. PubMed ID: 30148862
[TBL] [Abstract][Full Text] [Related]
55. HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
Waliany S; Neal JW; Engel-Nitz N; Lam C; Lin F; Park L; Le L; Nagasaka M
Clin Lung Cancer; 2024 Jun; 25(4):319-328.e1. PubMed ID: 38403548
[TBL] [Abstract][Full Text] [Related]
56. First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.
Zornosa C; Vandergrift JL; Kalemkerian GP; Ettinger DS; Rabin MS; Reid M; Otterson GA; Koczywas M; D'Amico TA; Niland JC; Mamet R; Pisters KM
J Natl Compr Canc Netw; 2012 Jul; 10(7):847-56. PubMed ID: 22773800
[TBL] [Abstract][Full Text] [Related]
57. Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.
Seung SJ; Hurry M; Walton RN; Evans WK
Curr Oncol; 2020 Aug; 27(4):e361-e367. PubMed ID: 32905294
[TBL] [Abstract][Full Text] [Related]
58. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
59. Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data.
Feliciano J; Gardner L; Hendrick F; Edelman MJ; Davidoff A
Lung Cancer; 2015 Jan; 87(1):59-64. PubMed ID: 25443272
[TBL] [Abstract][Full Text] [Related]
60. The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis.
Ahmed Z; Kennedy K; Subramanian J
Lung Cancer; 2021 Apr; 154():62-68. PubMed ID: 33626487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
